Dr Keith Tsui

Medopad

Keith is the lead for life science partnerships in the clinical product team. In addition, Keith is also responsible for developing the strategy to demonstrate outcome and evidence for remote patient monitoring within Medopad. Prior to Medopad, Keith was a management consultant at Carnall Farrar, a healthcare consulting firm. Keith completed his medical training at The University of Hong Kong and holds a MPhil in Bioscience Enterprise from University of Cambridge.

dont miss

Remote Patient Monitoring: Bringing the Hospital into the Home

Patients with rare and chronic disease spend 95% of their time outside hospital, where clinicians typically have no or intermittent access to patient health data.
Here, we explore how a remote patient monitoring solution can be applied within the care pathway for oncology, to improve visibility of patient progress, impact patient engagement, and improve pathway efficiencies. Oncology monitoring at King’s College Hospital, HCA, and Sussex Cancer Centre will be explored.

EVEN MORE SEMINARS

  • Mr Hamish Clouston: Speaking at the Oncology Convention

    Mr Hamish Clouston
    The Christie NHS Foundation Trust

    Surgical Management of Advanced Colonic and Rectal Malignancies.

  • Prantik Das: Speaking at the Oncology Convention

    Prantik Das
    University Hospital of Derby and Burton NHS Foundation Trust

    The Changing Landscape of Prostate Radiotherapy

  • Dr Natalie Cook: Speaking at the Oncology Convention

    Dr Natalie Cook
    University of Manchester/Christie NHS Foundation Trust

    Early phase trial options in prostate cancer

  • Dr Qamar Ghafoor: Speaking at the Oncology Convention

    Dr Qamar Ghafoor
    University Hospital Birmingham

    Stereotactive Radiotherapy Treatment for Primary Lung Cancers, and Oligometastasis to the Lungs.

  • Dr Abeer Shabaan: Speaking at the Oncology Convention

    Dr Abeer Shabaan
    Queen Elizabeth Hospital Birmingham & University of Birmingham

    Breast Pathology: Assessing tumour response to neoadjuvant chemotherapy and endocrine therapy– Pathological considerations